Drug Profile
Anti-MUC1 CAR-pNK cells - PersonGen Biomedicine
Alternative Names: Anti-MUC1 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-mucin1 chimeric antigen receptor natural killer cell therapy - PersonGen BiomedicineLatest Information Update: 18 Feb 2022
Price :
$50
*
At a glance
- Originator PersonGen Biomedicine
- Class Antineoplastics; CAR-NK cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Parenteral)
- 01 Jul 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (Parenteral) (NCT02839954)